Home
ArticlesArticlesLabman and TMRW partner for CryoRobot to revolutionize IVF labs with secure, automated cryogenic storage and RFID-enabled sample tracking. The partnership brings safety and efficiency gains, setting a new standard for fertility clinics worldwide.
TMRW Life Sciences and Labman have developed a next-generation IVF specimen storage and retrieval system that integrates biometric scanning, a custom cryogenic tank, and end-to-end digital tracking to improve safety, efficiency, and scalability in embryology labs. The CE‑marked CryoRobot Select aligns with FDA requirements, multiple ISO standards, and GDPR, and is now embedded in TMRW’s product pipeline for global deployment.
Conventional IVF workflows are vulnerable to mishandling, inefficient tracking, and suboptimal storage conditions that compound risk as frozen inventories grow, prompting an automation-first redesign of cryostorage management. The CryoRobot Select was engineered to directly address these gaps by reducing manual touchpoints, standardizing conditions, and creating a verifiable digital chain of custody at the sample level.
The platform pairs purpose-built hardware, a tailored cryogenic storage tank, and a robotic picker with software-enabled specimen identification using RFID tags unique to each patient sample. Embryologists gain global, real-time visibility and auditability over eggs and embryos, supported by biometric access control and continuous system checks to maintain optimal temperature and handling conditions.
In testing and verification, the technology demonstrated safer, more controlled handling environments for eggs and embryos stored within the TMRW ecosystem, providing added assurance to clinics and patients. Reported operational benefits include substantial reductions in storage and retrieval cycle times, consistent with automation-driven efficiencies that minimize potential points of failure compared with manual systems.
The CryoRobot Select received the EU CE Mark following FDA clearance, meeting rigorous safety and performance standards under European Medical Device Regulations and aligning with multiple ISO frameworks. The system’s data practices are designed to comply with GDPR and to support EMR integration and audit-ready traceability across the IVF laboratory workflow.
TMRW’s device engineering leadership highlights that replacing the earlier-generation automation with CryoRobot Select enables expansion into more clinics and markets thanks to a smaller footprint, shorter cycle times, and reduced user handling. The collaboration emphasized a risk-based development process to protect both the patient and specimen at every step of storage and retrieval.
This collaboration shows how specialized automation engineering and fertility technology can be combined to harden critical lab processes while simplifying daily operations for embryologists. As demand for cryopreservation scales, clinics adopting automated storage with digital specimen management are positioned to reduce errors, improve throughput, and strengthen patient confidence in chain-of-custody and safety controls.
Labman and TMRW partner for CryoRobot to establish a new benchmark for IVF cryostorage: high-volume capacity, precise tracking, and robust compliance in a compact, deployable form factor for global labs. By elevating consistency and accountability in the most sensitive stages of IVF, Labman and TMRW partner for CryoRobot to align clinical operations with the scale and expectations of modern fertility care. Ultimately, Labman and TMRW partner for CryoRobot to make specimen management safer and more efficient while reinforcing trust through demonstrable, digital traceability.
Clinics increasingly use AI and tech In IVF to rank embryos, personalize stimulation, and predict live-birth odds. Leaders must ensure validation, transparency, and bias controls while patients ask how tools are used, monitored, and explained.
The importance of genetic screening in In Vitro Fertilization (IVF) and its role in enhancing embryo selection to boost safety and success rates in assisted reproductive technology is noteworthy. It highlights various types of genetic screening methods, such as PGT-A and PGD, and their impact on reducing miscarriage risks and ensuring healthier pregnancies through genetic screening in IVF.
Laser-Assisted Hatching improves embryo implantation by gently opening the zona pellucida using advanced laser technology, supporting better IVF outcomes for select patients.
Digital nursing platforms are changing IVF treatment by allowing patients to receive care at home using telemedicine, mobile apps, and remote monitoring, giving them more control, convenience, and access to fertility services while still achieving similar results to traditional care.
IVF in 2025 is shifting from hype to evidence-based innovation. As precision, automation, AI, and genetic advances reshape fertility care, patients must distinguish proven breakthroughs from outdated add-ons. This guide examines five groundbreaking IVF technologies in 2025 to understand which advances genuinely improve outcomes
A groundbreaking clinical study from Lund University reveals that a simple oral swab test can identify which hormone treatment works best for individual women undergoing IVF. By matching personalized genetic profiles with appropriate hormone therapy, this innovative approach using oral swab test for personalized IVF treatment success increases pregnancy rates by 38% and could transform how fertility clinics optimize ovarian stimulation protocols globally.
